Chemical Approaches for Beta-cell Biology

Vetere, Amedeo; Parekh, Vishal S.; Modell, Ashley E.; Shoba, Veronika M.; Choudhary, Amit; Wagner, Bridget K.

doi:10.1039/9781839165498-00001

Cited by 1 publication

(1 citation statement)

References 276 publications

(271 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The derivatives of glibenclamide are considered fundamental sulfonyl ligands, and they are commonly used commercial fluorescent probes for ER-based live cell imaging, namely ER-Tracker Red (BODIPY™ TR-glibenclamide) and ER-tracker Green (BODIPY™ FL-glibenclamide), consist of both BODIPY and glibenclamide (Wijesooriya et al., 2019 ). While the glibenclamide-based ER targeting system exhibits lower cellular toxicity, the comparatively large molecular weight (MW) and exclusive pharmacokinetics and pharmacodynamics properties of glibenclamide may have unintended effects on the normal biological functions of the ER (Vetere et al., 2022 ). Thus it is recommended to use these ER-trackers at the lowest possible concentrations.…”

Section: Small Molecule-driven Receptor-mediated Er Targetingmentioning

confidence: 99%

Intricate subcellular journey of nanoparticles to the enigmatic domains of endoplasmic reticulum

Girigoswami,

Pallavi,

Girigoswami

2023

Drug Delivery

View full text Add to dashboard Cite

It is evident that site-specific systemic drug delivery can reduce side effects, systemic toxicity, and minimal dosage requirements predominantly by delivering drugs to particular pathological sites, cells, and even subcellular structures. The endoplasmic reticulum (ER) and associated cell organelles play a vital role in several essential cellular functions and activities, such as the synthesis of lipids, steroids, membrane-associated proteins along with intracellular transport, signaling of Ca 2+ , and specific response to stress. Therefore, the dysfunction of ER is correlated with numerous diseases where cancer, neurodegenerative disorders, diabetes mellitus, hepatic disorder, etc., are very common. To achieve satisfactory therapeutic results in certain diseases, it is essential to engineer delivery systems that can effectively enter the cells and target ER. Nanoparticles are highly biocompatible, contain a variety of cargos or payloads, and can be modified in a pliable manner to achieve therapeutic effectiveness at the subcellular level when delivered to specific organelles. Passive targeting drug delivery vehicles, or active targeting drug delivery systems, reduce the nonselective accumulation of drugs while reducing side effects by modifying them with small molecular compounds, antibodies, polypeptides, or isolated bio-membranes. The targeting of ER and closely associated organelles in cells using nanoparticles, however, is still unsymmetrically understood. Therefore, here we summarized the pathophysiological prospect of ER stress, involvement of ER and mitochondrial response, disease related to ER dysfunctions, essential therapeutics, and nanoenabled modulation of their delivery to optimize therapy.

show abstract

Section: Small Molecule-driven Receptor-mediated Er Targetingmentioning

confidence: 99%